

PRESS RELEASE

Ad hoc announcement pursuant to article 53 LR

LEPU Medical Technology(Beijing) Announces 2023 Semi-annual Report

Beijing, China, August 25, 2023- LEPU Medical Technology(Beijing) Co.,Ltd.(the “Company”) today announced its performance for the half-year of 2023:

The Company is a whole life-cycle solution provider in the field of cardiovascular diseases, and its business sectors are divided into medical devices, pharmaceutical, medical care solutions. The Company adheres to the medium-and long-term strategy of "innovation, consumption and internationalization" and is driven by multiple wheels to achieve long-term and steady business development. During the reporting period, the Company has realized an operating income of RMB 4301.4577 million, a net profit of RMB 961.4873 million attributable to shareholders of listed companies, a net profit of RMB 904.8747 million attributable to shareholders of listed companies after deducting non-recurring gains and losses, a net profit of RMB 975.1617 million attributable to shareholders of listed companies after deducting expenses related to equity incentives implemented by the Company, and a net cash flow of RMB 141.7016 million from operating activities. At the end of the reporting period, the Company's total assets were RMB 24439.7632 million, and the net assets attributable to shareholders of listed companies were RMB 15721.4988 million, with a weighted average return on equity of 6.39%.

Financial Results(unaudited)

	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022	% Change
Operating revenue(RMB)	4,301,457,705.65	5,333,506,938.54	-19.35%
Net profit attributable to shareholders of the Company (RMB)	961,487,273.99	1,268,027,645.71	-24.17%

Net profit attributable to shareholders of the Company after deducting non-recurring profit and loss (RMB)	904,874,709.56	1,263,510,359.96	-28.38%
Net cash flows from operating activities (RMB)	141,701,593.18	1,178,292,977.74	-87.97%
Basic earnings per share (RMB /share)	0.5163	0.7117	-27.46%
Diluted earnings per share (RMB /share)	0.5147	0.7039	-26.88%
Return on weighted average net assets	6.39%	10.69%	-4.30%

Full 2023 Semi-annual Report

The Full 2023 2023 Semi-annual Report is available on our website at

<https://en.lepumedical.com/investors/>.

Contact information

Ms. Weina Jiang

Phone: +86 010 80120622

E-mail: zqb@lepumedical.com

About LEPU

LEPU Medical Technology(Beijing) Co.,Ltd was the total-solution provider in the PRC across the full life cycle of cardiovascular disease management, with products and services encompassing medical devices, pharmaceuticals, and medical care solutions Company is one of the earliest companies in the PRC to offer coronary interventional products and have consolidated our first-mover advantage through relentless innovation since our inception in 1999. Our key products, namely, coronary drug-eluting stent, coronary bioresorbable scaffold, coronary drug-coated balloon, congenital heart disease occluder and coronary cutting balloon. Our leading R&D

expertise and capabilities have enabled us to develop and successfully commercialize a comprehensive portfolio of products. We focus our R&D efforts on unmet clinical needs. We have developed and commercialized the first fully biodegradable occluder in the world and many first Chinese brand products, such as coronary stent, cardiac pacemaker, bioresorbable scaffold and coronary cutting balloon. In addition, we are the first PRC company to apply AI technology to ECG devices. Furthermore, benefiting from our diverse technology platforms, we have developed over 80 product candidates for cardiovascular devices and peripheral artery devices across coronary artery diseases, structural heart diseases, cardiac rhythm management, electrophysiology and other segments.

Disclaimers

This announcement contains forward-looking statements, estimates, opinions and projections with respect to anticipated future performance of the Company ("forward-looking statements"). These forward-looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current views, expectations and assumptions of the management of the Company and involve significant known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. Any forward-looking statements included herein only speak as at the date of this release.